Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis

2010144 citationsJournal Articlehybrid Open Access

Authors

The UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology · Institute of Cancer Research

S M Edwards · Institute of Cancer Research

D. Gareth Evans · Institute of Cancer Research

Questa Hope · Royal Marsden NHS Foundation Trust

A. Norman · Royal Marsden NHS Foundation Trust

Yolanda Barbáchano · Royal Marsden NHS Foundation Trust

Sarah Bullock

Abstract

BRCA2 germline mutation is an independent prognostic factor for survival in PrCa. Such patients should not be managed with active surveillance as they have more aggressive disease.

Topics & Keywords

BRCA gene mutations in cancer Genetic factors in colorectal cancer Cancer Genomics and Diagnostics

UN Sustainable Development Goals

No poverty

Publication Details

Published in: British Journal of Cancer

Volume 103, Issue 6, pp. 918-924

DOI: 10.1038/sj.bjc.6605822

Field-Weighted Citation Impact: 4.73